Table S2. Clinical trials involving radioimmunoconjugates
Conjugate
Clinical trial
identifier
63 clinical trials
in
clinicaltrials.gov
Drug
Target
Stage
Cancer
Effects
90Yttrium
CD20
I, II, III, IV
Follicular lymphoma,
Relapsed And Refractory
NHL,
Relapsed And Refractory
MCL,
DLBCL,
CNS Lymphoma,
Low Grade NHL,
Multiple Myeloma,
Waldenstrom's
Macroglobulinemia
1-4
NCT01101581
NCT01147393
NCT01354457
90Yttrium
CD22
I, II
Relapsed/Refractory,
Aggressive NHL,
Follicular Lymphoma
, Relapsed or Refractory
CD22+ B-ALL
5-7
90Yttrium
Tac
I, II
Cutaneous CTCL, ATL
8
Anti-Tac
90YttriumLabetuzumab
NCT00001249
NCT00019227
NCT00040599
NCT00041652
NCT00041639
90
Carcinoemb
ryonic
antigen
(CEA)
I, II
Refractory
Metastatic/Recurrent
Colorectal Carcinomas
Recurrent,
Metastatic,
Unresectable Colorectal
and Breast Carcinomas
Refractory
Advanced/Metastatic
Pancreatic Carcinoma
Not yet available
90Yttrium-
NCT00072410
90Yttrium
Lewis Y
I
Advanced Ovarian Cancer
Not yet available
hu3S193
90YttriumDOTA-cG250
NCT00199875
90Yttrium
I
Advanced Renal Cancer
Not yet available
131Iodine
I, II, III
131Iodine-
NCT00291486
131Iodine
A33
I
huA33
131Iodine-CC49
NCT00025532
NCT00023933
131Iodine
TAG-72
I
Relapsed And Refractory
NHL,
HL, Multiple Myeloma,
Mantle Cell Lymphoma,
Metastatic Colorectal
Cancer
Gastrointestinal
Adenocarcinoma, Colon
Cancer
9-11
Tositumomab
38 clinical trials
in
clinicaltrials.gov
Carbonic
anhydrase
IX (CA IX)
CD20
131Iodine-
NCT00003102
131Iodine
I, II
Advanced Renal Cancer
14, 15
NCT01296204
NCT00199888
131Iodine
I
II
Multiple Myeloma
Refractory
Metastatic
Renal Cell Carcinoma
Not yet available
NCT00199862
124Iodine
carbonic
anhydrase
IX (CA IX)
CD138
Carbonic
anhydrase
IX (CA IX)
A33
I
Colorectal Cancer
Not yet available
NCT00916123
NCT00538668
NCT00859781
NCT00195039
NCT00967577
NCT00081172
177Lutetium
Prostate
specific
membrane
antigen
(PSMA)
Pilot study,
II
Metastatic
AndrogenIndependent
Prostate
Cancer, Relapsed Prostate
Cancer,
Nonprostate
Metastatic Solid Tumors
18, 19
90Yttrium-
Ibritumomab
tiuxetan
90Yttrium-
Epratuzumab
90Yttrium-
131Iodine-
Yttrium
cG250
131Iodine-BB4
124Iodine-
124Iodine
cG250
124IodinehuA33
177LutetiumJ591
12
13
16, 17
ALL = Acute Lymphoblastic Leukaemia; ATL = Adult T-Cell Leukaemia; CTCL = Cutaneous TCell Lymphoma; DLBCL = Diffuse Large B-Cell Lymphoma; HL = Hodgkin’s Lymphoma; MCL
= Mantle Cell Lymphoma; NHL = Non-Hodgkin’s Lymphoma
References
1.
Han EJ, Lee SE, Kim SH, et al. Clinical outcomes of post-remission therapy using (90)yttrium
ibritumomab tiuxetan (Zevalin(R)) for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol
2011.
2.
Vitolo U, Barosi G, Fanti S, et al. Consensus conference on the use of 90-yttrium-ibritumomab
tiuxetan therapy in clinical practice. A project of the Italian society of hematology. Am J Hematol
2010;85:147-55.
3.
Jacobs SA. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current
status and future prospects. Biologics 2007;1:215-27.
4.
Zhou Y, Zhang L, Romaguera J, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based
therapy and beyond. Am J Hematol 2008;83:144-9.
5.
Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with antiCD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's
lymphoma. J Clin Oncol 2010;28:3709-16.
6.
Bodet-Milin C, Kraeber-Bodere F, Dupas B, et al. Evaluation of response to fractionated
radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose
positron emission tomography. Haematologica 2008;93:390-7.
7.
Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in nonHodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal
antibody, epratuzumab. Clin Cancer Res 2005;11:5215-22.
8.
Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alphaexpressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995;86:4063-75.
9.
Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status
and future development. World J Gastroenterol 2010;16:5543-54.
10.
Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic
malignancies. Curr Opin Hematol 2007;14:632-8.
11.
Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with
131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Blood 2011;117:45-52.
12.
Chong G, Lee FT, Hopkins W, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal
carcinoma. Clin Cancer Res 2005;11:4818-26.
13.
Murray JL, Macey DJ, Kasi LP, et al. Phase II radioimmunotherapy trial with 131I-CC49 in
colorectal cancer. Cancer 1994;73:1057-66.
14.
Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of
radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin
Oncol 2005;23:6540-8.
15.
Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy
using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004;45:1412-21.
16.
Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal
carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal
masses: a phase I trial. Lancet Oncol 2007;8:304-10.
17.
Rice SL, Roney CA, Daumar P, et al. The next generation of positron emission tomography
radiopharmaceuticals in oncology. Semin Nucl Med 2011;41:265-82.
18.
Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled
monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol
2003;170:1717-21.
19.
Nakajima T, Mitsunaga M, Bander NH, et al. Targeted, Activatable, In Vivo Fluorescence Imaging
of Prostate-specific Membrane Antigen (PSMA)-positive Tumors Using the Quenched Humanized J591
Antibody-ICG Conjugate. Bioconjug Chem 2011.
Table S2: Details of the clinical trials involving radioimmunoconjugates (data gathered from US
clinicaltrials.gov, Clinical Trials register EU and available bibliography in sponsor an PubMed websites).